Legacy Pharma Inc Sezc
As of the edition of 20 October 2026, Legacy Pharma Inc Sezc runs 10 drugs, 10 of them marketed; it is on route A at 0 targets and on route B at 7 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 10 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Paroxetine | none listed | 1 |
| Pirfenidone | none listed | 0 |
| Azathioprine | none listed | 2 |
| Amifostine | none listed | 0 |
| Tizanidine | none listed | 3 |
| Sotalol | none listed | 3 |
| Auranofin | none listed | 0 |
| Naftifine | none listed | 0 |
| Alosetron | none listed | 1 |
| Clocortolone pivalate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 7 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where Legacy Pharma Inc Sezc needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.